DPYSL4

Across TCGA pan-cancer cohorts, DPYSL4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DPYSL4 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DPYSL4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DPYSL4 expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

LUAD, GBM, and PDAC are the cancer types where DPYSL4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.774	0.932	.030	9	view →
GBM	DFS	Quartile	All	0.855	0.663	.013	6	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	6	view →
CCRCC	OS	Quartile	III,IV	0.980	0.434	.024	2	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.482	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DPYSL4–LUAD (DFS)

Open the LUAD breakdown →